Saltz L - Search Results

1

Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer.

Saltz L, Badarinath S, Dakhil S, Bienvenu B, Harker WG, Birchfield G, Tokaz LK, Barrera D, Conkling PR, O'Rourke MA, Richards DA, Reidy D, Solit D, Vakiani E, Capanu M, Scales A, Zhan F, Boehm KA, Asmar L, Cohn A. Saltz L, et al. Clin Colorectal Cancer. 2012 Jun;11(2):101-11. doi: 10.1016/j.clcc.2011.05.006. Epub 2011 Nov 4. Clin Colorectal Cancer. 2012. PMID: 22055112 Clinical Trial.

2

Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.

Conti JA, Kemeny NE, Saltz LB, André AM, Grossano DD, Bertino JR. Conti JA, et al. Among authors: saltz lb. Cancer. 1995 Feb 1;75(3):769-74. doi: 10.1002/1097-0142(19950201)75:3<769::aid-cncr2820750304>3.0.co;2-5. Cancer. 1995. PMID: 7828126 Clinical Trial.

3

A fixed-ratio combination of uracil and Ftorafur (UFT) with low dose leucovorin. An active oral regimen for advanced colorectal cancer.

Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, Jeffers S, Leichman LP. Saltz LB, et al. Cancer. 1995 Feb 1;75(3):782-5. doi: 10.1002/1097-0142(19950201)75:3<782::aid-cncr2820750306>3.0.co;2-i. Cancer. 1995. PMID: 7828128 Clinical Trial.

4

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.

Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, Staton BA, Berkery R, Steger C, Eng M, Dietz A, Locker P, Kelsen DP. Saltz LB, et al. J Clin Oncol. 1996 Nov;14(11):2959-67. doi: 10.1200/JCO.1996.14.11.2959. J Clin Oncol. 1996. PMID: 8918493 Clinical Trial.

5

Adjuvant treatment of colorectal cancer.

Saltz LB, Kelsen DP. Saltz LB, et al. Annu Rev Med. 1997;48:191-202. doi: 10.1146/annurev.med.48.1.191. Annu Rev Med. 1997. PMID: 9046955 Review.

6

9-Aminocamptothecin by 72-hour continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma.

Saltz LB, Kemeny NE, Tong W, Harrison J, Berkery R, Kelsen DP. Saltz LB, et al. Cancer. 1997 Nov 1;80(9):1727-32. doi: 10.1002/(sici)1097-0142(19971101)80:9<1727::aid-cncr5>3.0.co;2-b. Cancer. 1997. PMID: 9351540 Clinical Trial.

7

Irinotecan in the first-line treatment of colorectal cancer.

Saltz LB. Saltz LB. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):54-8. Oncology (Williston Park). 1998. PMID: 9726092 Review.

8

Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors.

Saltz LB, Spriggs D, Schaaf LJ, Schwartz GK, Ilson D, Kemeny N, Kanowitz J, Steger C, Eng M, Albanese P, Semple D, Hanover CK, Elfring GL, Miller LL, Kelsen D. Saltz LB, et al. J Clin Oncol. 1998 Dec;16(12):3858-65. doi: 10.1200/JCO.1998.16.12.3858. J Clin Oncol. 1998. PMID: 9850031 Clinical Trial.

9

A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma.

O'Reilly EM, Ilson DH, Saltz LB, Heelan R, Martin L, Kelsen DP. O'Reilly EM, et al. Among authors: saltz lb. Cancer Invest. 1999;17(3):195-200. doi: 10.3109/07357909909021421. Cancer Invest. 1999. PMID: 10099658 Clinical Trial.

10

Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma.

Enzinger PC, Ilson DH, Saltz LB, Martin LK, Kelsen DP. Enzinger PC, et al. Among authors: saltz lb. Cancer. 1999 Mar 15;85(6):1213-7. doi: 10.1002/(sici)1097-0142(19990315)85:6<1213::aid-cncr1>3.0.co;2-n. Cancer. 1999. PMID: 10189124 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

509 results

Search Page

Filters